The 2nd AI-Machine Learning Clinical Development Summit 2019 is designed to help the industry harness AI and extract maximum value to achieve regulatory success and accelerate novel therapeutic products to market.
As clinical failure rates remain unsustainable and the vast amounts of patient data increases further, AI, data and clinical development and pharmacovigilance experts from across large pharma and biotech are gathered to discover the growing practical applications of AI and ML.
Now is a critical time for drug developers to make more data-driven decisions that lead to improved efficacy, safety and approval outcomes. Key stakeholders joined to make the scientific decisions and connections needed to succeed.
Designed with AI and R&D experts from the likes of GSK, Pfizer, Takeda, Celgene, AbbVie and academic KOLs, this year’s meeting encapsulated both the critical scientific and technical challenges and opportunities of implementing AI and ML to optimize your clinical development.
With 60+ thought-leaders that joined the AI-Machine Learning Clinical Development Summit, this meeting was an unrivalled opportunity to learn first-hand the growing practical applications of AI and ML.